Cytosorbents (CTSO) Misses Q2 EPS by 3c

Cytosorbents (NASDAQ: CTSO) reported Q2 EPS of ($0.14), $0.03 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $11.03 million.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Goldman Sachs Upgrades RENK Group AG (R3NK:GR) to Buy
• JPMorgan Upgrades Tyson (TSN) to Overweight